TY - JOUR
T1 - Therapeutic Angiogenesis for Peripheral Artery Disease
T2 - Lessons Learned in Translational Science
AU - Iyer, Sunil R.
AU - Annex, Brian H.
N1 - Funding Information:
Dr. Annex is supported by National Institute of Health grants 1R01 HL116455, 1R01 HL121635, and 2R01 HL101200. Dr. Iyer has reported that he has no relationships relevant to the contents of this paper to disclose. State-of-the-Art Review
Publisher Copyright:
© 2017 The Authors
PY - 2017/10
Y1 - 2017/10
N2 - Peripheral arterial disease (PAD) is a major health care problem. There have been limited advances in medical therapies, and a huge burden of symptomatic patients with intermittent claudication and critical limb ischemia who have limited treatment options. Angiogenesis is the growth and proliferation of blood vessels from existing vasculature. For approximately 2 decades, “therapeutic angiogenesis” has been studied as an investigational approach to treat patients with symptomatic PAD. Despite literally hundreds of positive preclinical studies, results from human clinical studies thus far have been disappointing. Here we present an overview of where the field of therapeutic angiogenesis stands today and examine lessons learned from previously conducted clinical trials. The objective is not to second-guess past efforts but to place the lessons in perspective to allow for trial success in the future to improve agent development, trial design, and ultimately, clinical outcomes for new therapeutics for PAD.
AB - Peripheral arterial disease (PAD) is a major health care problem. There have been limited advances in medical therapies, and a huge burden of symptomatic patients with intermittent claudication and critical limb ischemia who have limited treatment options. Angiogenesis is the growth and proliferation of blood vessels from existing vasculature. For approximately 2 decades, “therapeutic angiogenesis” has been studied as an investigational approach to treat patients with symptomatic PAD. Despite literally hundreds of positive preclinical studies, results from human clinical studies thus far have been disappointing. Here we present an overview of where the field of therapeutic angiogenesis stands today and examine lessons learned from previously conducted clinical trials. The objective is not to second-guess past efforts but to place the lessons in perspective to allow for trial success in the future to improve agent development, trial design, and ultimately, clinical outcomes for new therapeutics for PAD.
KW - angiogenesis
KW - critical limb ischemia
KW - gene therapy
KW - peripheral arterial disease
UR - http://www.scopus.com/inward/record.url?scp=85032669620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032669620&partnerID=8YFLogxK
U2 - 10.1016/j.jacbts.2017.07.012
DO - 10.1016/j.jacbts.2017.07.012
M3 - Review article
AN - SCOPUS:85032669620
SN - 2452-302X
VL - 2
SP - 503
EP - 512
JO - JACC: Basic to Translational Science
JF - JACC: Basic to Translational Science
IS - 5
ER -